Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dynavax has announced the efficacy data from two phase 3 studies of Heplisav, an investigational vaccine, in immunizing persons with diabetes from Hepatitis B.
Subscribe to our email newsletter
Heplisav is an investigational adult hepatitis B vaccine, which in earlier Phase 3 trials, showed increased, rapid protection with fewer doses than current licensed vaccines.
Both the studies showed that Heplisav provides faster, more and longer-lasting immunity in persons with diabetes than the vaccine, Engerix-B.
The trial enrolled 218 subjects with diabetes of which 179 were administered with Heplisav and 39 with Engerix-B.
The seroprotection rates (SPRs) for Heplisav were superior over Engerix-B at weeks 8 through 52.